Epilepsy News and Research

Latest Epilepsy News and Research

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

New vaccine leads to dramatic fall in meningitis A cases

Burkina Faso, Mali, and Niger report the lowest number of confirmed meningitis A cases ever recorded during an epidemic season this year following the successful introduction of a new vaccine that could eliminate the primary cause of the deadly disease from Africa's meningitis belt, announced the Meningitis Vaccine Project (MVP) today, which spearheaded development of the vaccine.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Older people who engage in moderate to intense exercise less likely to have silent strokes

Older people who regularly exercise at a moderate to intense level may be less likely to develop the small brain lesions, sometimes referred to as "silent strokes," that are the first sign of cerebrovascular disease, according to a new study published in the June 8, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Study finds consistent link between Parkinson's disease and melanoma

An analysis of several studies shows that people with Parkinson's disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases.

7 Jun 2011

Study shows cognitive impairment is evident in preschool children

A recent study has shown that cognitive impairment is evident early on in preschool children with epilepsy, consistent with results of similar studies in older children.

3 Jun 2011

Insight into beneficial epilepsy treatments for children with autism

Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.

3 Jun 2011

Patch-clamp recording reveals subtle differences between two neurotransmitter-gated ion channels

Using a high-resolution single-molecule study technique, University of Illinois researchers have seen the very subtle differences between two branches of an important family of neurotransmitter-gated ion channels.

3 Jun 2011

Cyberonics net sales increase 14% to $190.5 million for fiscal 2011

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the fourth quarter and fiscal year ended April 29, 2011.

2 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

Stress does not appear to increase risk of developing multiple sclerosis

Contrary to earlier reports, a new study finds that stress does not appear to increase a person's risk of developing multiple sclerosis. The research is published in the May 31, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

31 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

Precision ophthalmic tint lenses reduce migraine, study shows

Precision tinted lenses have been used widely to reduce visual perceptual distortions in poor readers, and are increasingly used for migraine sufferers, but until now the science behind these effects has been unclear.

26 May 2011

The Rockefeller University to honor pioneering memory researcher with Pearl Meister Greengard Prize

Brenda Milner, Ph.D., a pioneer in the field of cognitive neuroscience whose discoveries revolutionized the understanding of memory, will be awarded the 2011 Pearl Meister Greengard Prize from The Rockefeller University.

26 May 2011

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

Study provides insight into effective treatments for autism spectrum disorder, seizures

Roughly 25-35% of individuals with autism eventually develop seizures and many of the remainder have subclinical seizure-like brain activity. However, little is known about which traditional epilepsy treatments and commonly used non-traditional alternative treatments are effective for treating seizures or epilepsy in children and adults with autism spectrum disorder.

25 May 2011

African-Americans with multiple sclerosis have lower vitamin D levels

African-Americans who have multiple sclerosis have lower vitamin D levels than African-Americans who don't have the disease, according to a study published in the May 24, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Epilepsy News and Research

Latest Epilepsy News and Research

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

New vaccine leads to dramatic fall in meningitis A cases

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Older people who engage in moderate to intense exercise less likely to have silent strokes

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Study finds consistent link between Parkinson's disease and melanoma

Study shows cognitive impairment is evident in preschool children

Insight into beneficial epilepsy treatments for children with autism

Patch-clamp recording reveals subtle differences between two neurotransmitter-gated ion channels

Cyberonics net sales increase 14% to $190.5 million for fiscal 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Stress does not appear to increase risk of developing multiple sclerosis

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Precision ophthalmic tint lenses reduce migraine, study shows

The Rockefeller University to honor pioneering memory researcher with Pearl Meister Greengard Prize

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Study provides insight into effective treatments for autism spectrum disorder, seizures

African-Americans with multiple sclerosis have lower vitamin D levels

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Epilepsy News and Research

Latest Epilepsy News and Research

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in